Novartis AG said a new experimental medicine improved motor function in children with a form of spinal muscular atrophy, the devastating disorder targeted by its gene therapy Zolgensma, in an advanced study.
Novartis Says Drug Helps Children With Spinal Atrophy in Study
Estimated read time
1 min read
+ There are no comments
Add yours